News

Studies: Doctors fear retaliation for telling the truth (Morning Read)

The American Medical Association has an interesting collection of news about doctors and how successfully and truthfully they work with patients. Each of these studies reports on a different aspect of doctor/patient communications: Study: ‘I’m sorry’ price tag still too high Study: Med students learning ‘defensive medicine’ early Study: Non-compliant patients need conversation, not lecturing  […]

The American Medical Association has an interesting collection of news about doctors and how successfully and truthfully they work with patients. Each of these studies reports on a different aspect of doctor/patient communications:

One doctor has his own critique of television news and its coverage of effectiveness of anti-depressants and statins. Dr. Steven Greer of CurrentTV thinks a change in potential ad revenue could be affecting the amount of coverage about the effectiveness of statins and anti-depressants. Some of these drugs are going off patent, which means that TV advertising budgets for these medicines will almost disappear. 60 Minutes just did a less-than-timely segment on this news which is about a month old.

While antidepressant manufacturers may have money worries, Corcept is celebrating its latest financial news. The FDA approved the company’s Korlym (mifepristone) last week for the first-ever treatment of Cushing’s syndrome. The company’s shares rose more than 40% in after-hours trading when the news broke.

The mobile health technology company AirStrip also recently got a big financial vote of confidence. A new investment will allow the firm to expand the rollout of AirStrip Cardiology as well as the company’s other offerings.  Health Insight Capital, a subsidiary of HCA, is confident in this company that  creating the first iPhone medical app to secure FDA 510(k) approval.

Airstrip builds applications on its AppPoint platform that collects patient data from hospital monitoring systems and sends it to a doctor’s smart phone.

How well does your state support economic development for life science businesses? Two experts from BIO highlighted successes in many states as they judged various legislative and economic efforts on these criteria:

  • State legislative strategies
  • Supporting bioscience industry with venture capital and discovery funds
  • Incubators and economic development centers

They reported that forty-two states now support programs that provide commercialization assistance to technology companies in an effort to more smoothly transition invention into innovation in the marketplace.

They also recognized The North Carolina Biotechnology Center as the oldest organization of its kind in the world. The Center provides business loans, support for collaborative research projects, assistance aimed at connecting early-stage companies with larger corporations andaccess to investors along with other services.

Topics